IBDEI21P ; ; 06-AUG-2015
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;JUN 29, 2015
 Q:'DIFQR(358.4)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.4)
 ;;=^IBE(358.4,
 ;;^UTILITY(U,$J,358.4,0)
 ;;=IMP/EXP SELECTION GROUP^358.4I^2062^2062
 ;;^UTILITY(U,$J,358.4,1,0)
 ;;=ACOUSTIC NERVE INJURIES^1^1
 ;;^UTILITY(U,$J,358.4,2,0)
 ;;=AUDITORY DISORDERS^2^1
 ;;^UTILITY(U,$J,358.4,3,0)
 ;;=BALANCE DISORDERS^3^1
 ;;^UTILITY(U,$J,358.4,4,0)
 ;;=BAROTRAUMA^4^1
 ;;^UTILITY(U,$J,358.4,5,0)
 ;;=EAR DISEASE^5^1
 ;;^UTILITY(U,$J,358.4,6,0)
 ;;=FOREIGN BODIES^5^1
 ;;^UTILITY(U,$J,358.4,7,0)
 ;;=HEARING LOSS^6^1
 ;;^UTILITY(U,$J,358.4,8,0)
 ;;=NOISE INJURIES^7^1
 ;;^UTILITY(U,$J,358.4,9,0)
 ;;=NYSTAGMUS^8^1
 ;;^UTILITY(U,$J,358.4,10,0)
 ;;=OTOTOXICITY^9^1
 ;;^UTILITY(U,$J,358.4,11,0)
 ;;=PURPOSE OF ENCOUNTER/HEALTH STATUS^10^1
 ;;^UTILITY(U,$J,358.4,12,0)
 ;;=ANEMIA^1^2
 ;;^UTILITY(U,$J,358.4,13,0)
 ;;=ARTIFICIAL OPENING STATUS^2^2
 ;;^UTILITY(U,$J,358.4,14,0)
 ;;=BREASTS and GYN NEOPLASMS^3^2
 ;;^UTILITY(U,$J,358.4,15,0)
 ;;=COAGULATION DISORDERS^4^2
 ;;^UTILITY(U,$J,358.4,16,0)
 ;;=COUNSELING AND SCREENING^5^2
 ;;^UTILITY(U,$J,358.4,17,0)
 ;;=GENITOURINARY NEOPLASMS^6^2
 ;;^UTILITY(U,$J,358.4,18,0)
 ;;=GI CANCER^7^2
 ;;^UTILITY(U,$J,358.4,19,0)
 ;;=HEAD NECK AND LUNGS NEOPLASMS^8^2
 ;;^UTILITY(U,$J,358.4,20,0)
 ;;=HEMOGLOBINOPATHIES^9^2
 ;;^UTILITY(U,$J,358.4,21,0)
 ;;=LYMPHOID NEOPLASMS^10^2
 ;;^UTILITY(U,$J,358.4,22,0)
 ;;=METASTATIC SITES^11^2
 ;;^UTILITY(U,$J,358.4,23,0)
 ;;=MALIGNANT NEOPLASMS OF OTHER SITES^12^2
 ;;^UTILITY(U,$J,358.4,24,0)
 ;;=MYELOID NEOPLASMS AND DISORDERS^13^2
 ;;^UTILITY(U,$J,358.4,25,0)
 ;;=NEOPLASM OF UNCERTAIN BEHAVIOR^14^2
 ;;^UTILITY(U,$J,358.4,26,0)
 ;;=NEOPLASM OF UNSPECIFIED NATURE^15^2
 ;;^UTILITY(U,$J,358.4,27,0)
 ;;=PERSONAL HISTORY^16^2
 ;;^UTILITY(U,$J,358.4,28,0)
 ;;=ACUTE RENAL FAILURE^1^3
 ;;^UTILITY(U,$J,358.4,29,0)
 ;;=CARDIOVASCULAR^2^3
 ;;^UTILITY(U,$J,358.4,30,0)
 ;;=CHRONIC KIDNEY DISEASE^3^3
 ;;^UTILITY(U,$J,358.4,31,0)
 ;;=CONTACT/EXPOSURE TO COM D^4^3
 ;;^UTILITY(U,$J,358.4,32,0)
 ;;=DERMATOLOGY^5^3
 ;;^UTILITY(U,$J,358.4,33,0)
 ;;=DIABETES W/ COMPLICATIONS^6^3
 ;;^UTILITY(U,$J,358.4,34,0)
 ;;=DIABETES W/O COMPLICATION^7^3
 ;;^UTILITY(U,$J,358.4,35,0)
 ;;=EENT^8^3
 ;;^UTILITY(U,$J,358.4,36,0)
 ;;=ENDOCRINE/METABOLIC^9^3
 ;;^UTILITY(U,$J,358.4,37,0)
 ;;=GASTROENTEROLOGY^10^3
 ;;^UTILITY(U,$J,358.4,38,0)
 ;;=GENITOURINARY^11^3
 ;;^UTILITY(U,$J,358.4,39,0)
 ;;=HEMATOLOGY/ONCOLOGY^12^3
 ;;^UTILITY(U,$J,358.4,40,0)
 ;;=HISTORY & STATUS POST^13^3
 ;;^UTILITY(U,$J,358.4,41,0)
 ;;=INFECTIOUS DISEASE^14^3
 ;;^UTILITY(U,$J,358.4,42,0)
 ;;=INFLAMMATORY/INF LUNG DX^15^3
 ;;^UTILITY(U,$J,358.4,43,0)
 ;;=INTERSTITIAL DISEASE^16^3
 ;;^UTILITY(U,$J,358.4,44,0)
 ;;=MENTAL HEALTH^17^3
 ;;^UTILITY(U,$J,358.4,45,0)
 ;;=MUSCULOSKELETAL^18^3
 ;;^UTILITY(U,$J,358.4,46,0)
 ;;=NEUROLOGY^19^3
 ;;^UTILITY(U,$J,358.4,47,0)
 ;;=OBSTRUCTIVE AIRWAY DISEASE^20^3
 ;;^UTILITY(U,$J,358.4,48,0)
 ;;=ORAL CAVITY^21^3
 ;;^UTILITY(U,$J,358.4,49,0)
 ;;=OTHER REASONS^22^3
 ;;^UTILITY(U,$J,358.4,50,0)
 ;;=PAIN^23^3
 ;;^UTILITY(U,$J,358.4,51,0)
 ;;=PERSONAL HX OF CANCER^24^3
 ;;^UTILITY(U,$J,358.4,52,0)
 ;;=PLEURAL DISEASE^25^3
 ;;^UTILITY(U,$J,358.4,53,0)
 ;;=PNEUMONIA^26^3
 ;;^UTILITY(U,$J,358.4,54,0)
 ;;=PULMONARY VASCULAR DISEASE^27^3
 ;;^UTILITY(U,$J,358.4,55,0)
 ;;=RESPIRATORY^28^3
 ;;^UTILITY(U,$J,358.4,56,0)
 ;;=SECONDARY DIABETES^29^3
 ;;^UTILITY(U,$J,358.4,57,0)
 ;;=SIGNS, SYMPTOMS, CONDITIONS^30^3
 ;;^UTILITY(U,$J,358.4,58,0)
 ;;=SLEEP DISORDERS^31^3
 ;;^UTILITY(U,$J,358.4,59,0)
 ;;=THROMBO EMBOLIC DISEASE^32^3
 ;;^UTILITY(U,$J,358.4,60,0)
 ;;=TUMOR^33^3
 ;;^UTILITY(U,$J,358.4,61,0)
 ;;=VASCULAR^34^3
 ;;^UTILITY(U,$J,358.4,62,0)
 ;;=INJURIES^5^4
 ;;
 ;;$END ROU IBDEI21P
